Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer.

Ho PL, Lay EJ, Jian W, Parra D, Chan KS.

Cancer Res. 2012 Jul 1;72(13):3135-42. doi: 10.1158/0008-5472.CAN-11-3195. Epub 2012 Apr 24.

2.

Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways.

Pan Q, Yang GL, Yang JH, Lin SL, Liu N, Liu SS, Liu MY, Zhang LH, Huang YR, Shen RL, Liu Q, Gao JX, Bo JJ.

J Exp Clin Cancer Res. 2015 Aug 7;34:77. doi: 10.1186/s13046-015-0183-0.

3.

Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma.

Shin K, Lim A, Odegaard JI, Honeycutt JD, Kawano S, Hsieh MH, Beachy PA.

Nat Cell Biol. 2014 May;16(5):469-78. doi: 10.1038/ncb2956. Epub 2014 Apr 20. Erratum in: Nat Cell Biol. 2014 Jun;16(6):620.

4.

Molecular pathways of urothelial development and bladder tumorigenesis.

Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C.

Urol Oncol. 2010 Jul-Aug;28(4):401-8. doi: 10.1016/j.urolonc.2009.04.019. Review.

PMID:
20610278
5.

Tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine as the basis for urothelial carcinogenesis.

He Z, Kosinska W, Zhao ZL, Wu XR, Guttenplan JB.

Mutat Res. 2012 Feb 18;742(1-2):92-5. doi: 10.1016/j.mrgentox.2011.11.015. Epub 2011 Dec 4.

PMID:
22155125
6.

Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice.

Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, Glode LM, Agarwal R.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3248-55.

8.

Normal and neoplastic urothelial stem cells: getting to the root of the problem.

Ho PL, Kurtova A, Chan KS.

Nat Rev Urol. 2012 Oct;9(10):583-94. doi: 10.1038/nrurol.2012.142. Epub 2012 Aug 14. Review.

9.

Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine.

Dunois-Lardé C, Levrel O, Brams A, Thiery JP, Radvanyi F.

Mol Carcinog. 2005 Mar;42(3):142-9.

PMID:
15690367
10.

Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation.

Zhang ZT, Pak J, Huang HY, Shapiro E, Sun TT, Pellicer A, Wu XR.

Oncogene. 2001 Apr 12;20(16):1973-80.

11.

Downregulation of glutathione S-transferase M1 protein in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced mouse bladder carcinogenesis.

Chuang JJ, Dai YC, Lin YL, Chen YY, Lin WH, Chan HL, Liu YW.

Toxicol Appl Pharmacol. 2014 Sep 15;279(3):322-30. doi: 10.1016/j.taap.2014.06.018. Epub 2014 Jul 3.

PMID:
24998975
12.

Susceptibility of p27 kip1 knockout mice to urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine may not simply be due to enhanced proliferation.

Hikosaka A, Ogawa K, Sugiura S, Asamoto M, Takeshita F, Sato SY, Nakanishi M, Kohri K, Shirai T.

Int J Cancer. 2008 Mar 15;122(6):1222-8.

13.

Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.

Hsu JW, Hsu I, Xu D, Miyamoto H, Liang L, Wu XR, Shyr CR, Chang C.

Am J Pathol. 2013 May;182(5):1811-20. doi: 10.1016/j.ajpath.2013.01.018. Epub 2013 Mar 13.

14.

A histopathological mapping study of the urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in dogs.

Okajima E, Ozono S, Yoshida K, Samma S, Momose H, Iwai A, Uemura H, Tabata S, Tsumatani K, Hirao Y, Tsunemi K.

Urol Res. 1997;25(5):315-23.

PMID:
9373911
15.

Alterations of beta- and gamma-catenin in N-butyl-N-(-4-hydroxybutyl)nitrosamine-induced murine bladder cancer.

Shiina H, Igawa M, Urakami S, Shigeno K, Yoneda T, Terashima M, Deguchi M, Ribeiro-Filho L, Dahiya R.

Cancer Res. 2001 Oct 1;61(19):7101-9.

16.

E-cadherin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in rats.

Oliveira PA, Colaço A, De la Cruz LF, Lopes P, Lopes C.

J Exp Clin Cancer Res. 2006 Sep;25(3):425-32.

PMID:
17167984
17.
18.

Time- and dose-dependent induction of invasive urinary bladder cancers by N-ethyl-N-(4-hydroxybutyl)nitrosamine in B6C3F1 mice.

Tamano S, Hagiwara A, Suzuki E, Okada M, Shirai T, Fukushima S.

Jpn J Cancer Res. 1991 Jun;82(6):650-6.

PMID:
1906851
19.

[Molecular changes in development and progression of urothelial carcinoma].

Hartmann A.

Verh Dtsch Ges Pathol. 2003;87:172-84. Review. German.

PMID:
16888910
20.

Suppression of ERβ signaling via ERβ knockout or antagonist protects against bladder cancer development.

Hsu I, Chuang KL, Slavin S, Da J, Lim WX, Pang ST, O'Brien JH, Yeh S.

Carcinogenesis. 2014 Mar;35(3):651-61. doi: 10.1093/carcin/bgt348. Epub 2013 Oct 22.

PMID:
24148819

Supplemental Content

Support Center